Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Blood (2023) 142 (Supplement 1): 4437.

https://doi.org/10.1182/blood-2023-188449

Published: 2023

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

Clare Gould, Colm Keane, MD, Valentine Murigneux, M.Sc., Harald Oey, Jonathan Ellis, PhD, Simone Birch, MBBS, Jay Gunawardana, PhD, Dipti Talaulikar, Mark S. Hertzberg, MD PhD, Kimberley Jones, Maher K. Gandhi, PhD

Blood (2019) 134 (Supplement_1): 2778.

https://doi.org/10.1182/blood-2019-126537

Published: 2019

Journal Articles

Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL

Frank Vari, David Arpon, Colm Keane, Mark S. Hertzberg, Dipti Talaulikar, Sanjiv Jain, Qingyan Cui, Erica Han, Josh Tobin, Robert Bird, Donna Cross, Annette Hernandez, Clare Gould, Simone Birch, Maher K. Gandhi

Blood (2018) 131 (16): 1809–1819.

https://doi.org/10.1182/blood-2017-07-796342

Published: 2018

Includes: Supplemental data

Journal Articles

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Bradstock Kenneth, Emma Link, DPhil, Juliana Di Iulio, BAppSc, PhD, Jeff Szer, MB, BS, FRACP, Paula Marlton, MBBS, FRCPA, FRACP, Andrew Wei, MBBS, PhD, Arno Enno, MB,BS,FRCPA, FRACP, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Ian D. Lewis, MBBS PhDFRACP FRCPA, James D'Rozario, MB BS FRACP, Luke Coyle, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Philip Campbell, MB ChB FRACP FRCPA, Michael Francis Leahy, FRACP, Uwe H Hahn, MDFGCP FRCPA, Paul Cannell, MD, Campbell Tiley, MBBS,FRACP, FRCPA, Raymond M. Lowenthal, MD FRACP, FRCP, John Moore, MBBS, MD FRACP , FRCPA, Kimberly Cartwright, FRACP,MDFRCPA, Ilona Cunningham, John Taper, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Andrew W. Roberts, MBBS PhD, Warwick John Benson, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Sandra F. Deveridge, MDBSc,FRACP,FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K. Mills, MBBS, FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Peter G Bardy, MBBS, FRACP, FRCPA, Lynda Campbell, John F. Seymour, MD

Blood (2016) 128 (22): 338.

https://doi.org/10.1182/blood.V128.22.338.338

Published: 2016

Journal Articles

A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+ Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma

Maher K Gandhi, PhDFRACP FRCPath FRCP, David Arpon, Colm Keane, Erica Han, Josh Tobin, MD, Robert Bird, FRACP, FRCP, FRCPA, MBBS, MRCP, Mark S Hertzberg, MBBS PhD FRACP FRCPA, Marlene Self, Donna Cross, Annette Hernandez, BS, Frank Vari, PhD

Blood (2016) 128 (22): 918.

https://doi.org/10.1182/blood.V128.22.918.918

Published: 2016

Journal Articles

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Blood (2016) 128 (22): 939.

https://doi.org/10.1182/blood.V128.22.939.939

Published: 2016

Journal Articles

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Blood (2015) 126 (23): 815.

https://doi.org/10.1182/blood.V126.23.815.815

Published: 2015

Journal Articles

Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia – a Multicentre Australian Experience: Prognostic Factors for Survival and Relapse

Ashish R. Bajel, MBBS, FRACP, FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Andrew Boon Ming Lim, MBBS, FRACP, FRCPA, Sasanka Handunnetti, MBBS, Bartlomiej Getta, MBBS,, Philip A Thompson, MBBS, FRACP, FRCPA, Matthew P.F. Wright, MBBS,FRCPA,FRACP, Matthew Greenwood, MD FRACP, FRCPA, Mark S Hertzberg, MBBS PhDFRACP FRCPA, David J. Curtis, MD, PhD, Jeffrey Szer, MBBS, FRACP, Glen A Kennedy, MBBS, FRACP, FRCPA, David Ritchie, MBBS, PhD FRACP, FRCPA

Blood (2014) 124 (21): 1927.

https://doi.org/10.1182/blood.V124.21.1927.1927

Published: 2014

Journal Articles

Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Thierry Fest, MD PhD, James R Cerhan, MD PhD, Maher K Gandhi, PhD FRACP, FRCPath, FRCP, Imane Azzaoui, PhD, Pauline Crooks, BSc, Matthew J Maurer, MS, Noel Milpied, MD PhD, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Thierry Lamy, MD PhD, Stephen M. Ansell, MD PhD, Susan L Slager, PhD, Andrew L. Feldman, MD, Mikael Roussel, MD PhD, Thomas M Habermann, MD, Herve Ghesquieres, MD PhD, Thomas E. Witzig, MD, Brian K Link, MD, Delphine Rossille, PhD

Blood (2014) 124 (21): 2998.

https://doi.org/10.1182/blood.V124.21.2998.2998

Published: 2014

Journal Articles

Maintenance Lenalidomide for Adults Aged 18-65 Years with AML in First Complete Remission after Intensive Chemotherapy: A Phase Ib Dose-Escalation Study of the Australasian Leukemia and Lymphoma Group (ALLG)

Andrew Wei, MBBS, PhD, Ian D Lewis, MBBS, PhD, Uwe Hahn, MD, Gavin Cull, MBBS, DM, FRACP, FRCPA, Anoop Enjeti, MBBS, MD FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Simon Z. He, MBBS,FRACP,FRCPA, Mark S Hertzberg, MBBS PhDFRACP FRCPA, John F Seymour, MBBS, FRACP, PhD

Blood (2014) 124 (21): 944.

https://doi.org/10.1182/blood.V124.21.944.944

Published: 2014

Journal Articles

KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies

Ronan T Swords, MD PhD FRCPI, FRCPath, Andrew H Wei, MBBS, PhD, Simon Durrant, MBBS, MRCS, LRCP, FRCP, FRCPat, Anjali S. Advani, MD, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Ian D Lewis, MBBS, PhD, Peter L. Greenberg, MD PhD, Jorge E. Cortes, MD, Geoff T Yarranton, PhD, Jackie M. Walling, MBChB, PhD, Jeffrey E. Lancet, MD

Blood (2014) 124 (21): 3756.

https://doi.org/10.1182/blood.V124.21.3756.3756

Published: 2014

Journal Articles

Final Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Trial: All- Trans Retinoic Acid (ATRA), Intravenous Arsenic Trioxide (ATO) and Idarubicin (IDA) As Initial Therapy for Acute Promyelocytic Leukemia (APL)

Harry J Iland, MBBS FRACP FRCPA, Marnie Collins, BCom BSc(Hons), Mark S Hertzberg, MBBS PhDFRACP FRCPA, Michael Seldon, MBBS FRACP FRCPA, Andrew P Grigg, MBBS FRACP FRCPA MD, Frank Firkin, MBBS PhDFRACP FRCPA, Shane G Supple, BSc(Hons) PhD, Lynda J Campbell, Kenneth F Bradstock, MBBS PhDFRACP FRCPA, John F Seymour, MBBS, FRACP, PhD

Blood (2014) 124 (21): 375.

https://doi.org/10.1182/blood.V124.21.375.375

Published: 2014

Journal Articles

Utility Of Non-Invasive Monitoring Of Circulating Tumor DNA At Diagnosis, Interim Therapy, and Relapse Of DLBCL Using High-Throughput Sequencing Of Immunoglobulin Genes

Michael R Green, PH.D., Scott Bratman, M.D., Chih Long Liu, Ph.D., Kazuhiro Takahashi, Cynthia Glover, Colm Keane, MB BCh BAO MSc MRCPI FRCPath, Shingo Kihira, Katie Kong, Malek Faham, MD, PhD, Corbelli Karen, David B. Miklos, MD, PhD, Ranjana H. Advani, MD, Ronald Levy, MD, Mark S. Hertzberg, MBBS, PhD, FRACP, FRCPA, Maher K Gandhi, Maximilian Diehn, Ash A. Alizadeh, MD, PhD

Blood (2013) 122 (21): 4264.

https://doi.org/10.1182/blood.V122.21.4264.4264

Published: 2013

Journal Articles

A Phase I Study Of KB004, a Novel Non-Fucosylated humaneered® Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies

Jeffrey E Lancet, MD, Andrew H Wei, MBBS, PhD, Simon TS Durrant, Mark S. Hertzberg, MBBS, PhD, FRACP, FRCPA, Ronan T. Swords, MD, PhD, FRCPI, FRCPath, Ian D Lewis, MB, BS, PhD, Brian Jonas, MD, PhD, Jorge E. Cortes, MD, Geoffrey Yarranton, PhD, Jackie M. Walling, MBChB, PhD

Blood (2013) 122 (21): 3838.

https://doi.org/10.1182/blood.V122.21.3838.3838

Published: 2013

Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2012) 120 (21): 3771.

https://doi.org/10.1182/blood.V120.21.3771.3771

Published: 2012

Journal Articles

Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival

Douglas E Joshua, MBBS, DPhil, Mark S Hertzberg, MD, PhD, Bradley Auguston, Andrew Spencer, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, John Bashford, MBBS, FRACP, FRCPA, Lynda J Campbell, Eleanor Ashurst, Jacquelyn Wade, Michael C. Copeman, DPhil, FRACP, Belinda E Butcher, BSc(Hons) MBiostat PhD, Miles Prince, MD, FRACP, FRCPA

Blood (2012) 120 (21): 4065.

https://doi.org/10.1182/blood.V120.21.4065.4065

Published: 2012

Journal Articles

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD. FFSc(RCPA), Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA

Blood (2011) 118 (21): 451.

https://doi.org/10.1182/blood.V118.21.451.451

Published: 2011

Journal Articles

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL,

Maher K Gandhi, PhD, FRACP, FRCPath, FRCP, Mark S. Hertzberg, MD, PhD, Erica Han, John F. Seymour, MD, PhD, Rodney Hicks, MB BS, MD, FRACP, Devinder S Gill, MD, Colm Keane, MB BCh BAO MSc MRCPI FRCPath, Pauline Crooks, Kristen Radford, PhD, Frank Vari, Phd

Blood (2011) 118 (21): 3673.

https://doi.org/10.1182/blood.V118.21.3673.3673

Published: 2011

NARROW

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+ Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia – a Multicentre Australian Experience: Prognostic Factors for Survival and Relapse

Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Maintenance Lenalidomide for Adults Aged 18-65 Years with AML in First Complete Remission after Intensive Chemotherapy: A Phase Ib Dose-Escalation Study of the Australasian Leukemia and Lymphoma Group (ALLG)

KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies

Final Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Trial: All- Trans Retinoic Acid (ATRA), Intravenous Arsenic Trioxide (ATO) and Idarubicin (IDA) As Initial Therapy for Acute Promyelocytic Leukemia (APL)

Utility Of Non-Invasive Monitoring Of Circulating Tumor DNA At Diagnosis, Interim Therapy, and Relapse Of DLBCL Using High-Throughput Sequencing Of Immunoglobulin Genes

A Phase I Study Of KB004, a Novel Non-Fucosylated humaneered® Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only